Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
NIAGARA Trial Results Show Durvalumab/Chemo Improves EFS, OS in Cisplatin-Eligible MIBC
September 15th 2024In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.
Read More